Actavis plc and Forest Laboratories, Inc. have each scheduled shareholder meetings for Tuesday, June 17, 2014 in connection with Actavis’ $25-billion pending acquisition of Forest Laboratories.

Both meetings are being held to seek shareholders’ approval in connection with the merger and related matters. Actavis will hold its meeting in Dublin, Ireland, and Forest Laboratories will hold its meeting in New York. 

Actavis filed a registration statement on Form S-4 with the US Securities and Exchange Commission on March 25, 2014 and amended it on May 2, 2014,  which includes a joint proxy statement of Actavis and Forest, which was declared effective on May 2, 2014. 

In February 2014, Actavis agreed to acquire Forest Laboratories for approximately $25 billion. If approved ,the combined specialty pharmaceutical company would have combined annual sales of approximately $15 billion.

Source: Actavis